Voyager Therapeutics is a leading biotechnology company that focuses on unlocking breakthroughs in AAV gene therapy and developing best-in-class treatments for central nervous system (CNS) and other diseases. With their innovative RNA-driven TRACER screening platform, Voyager has created novel AAV capsids that offer greater specificity, lower doses, and fewer off-target risks compared to conventional AAV serotypes. These capsids not only power their internal product development but also drive external partnerships, aiming to elevate the field of gene therapy to its highest potential.

Voyager sees each step in their journey as progress toward unlocking the full potential of gene therapy. They believe this breakthrough has the power to positively alter the lives of millions of people. Recent achievements include expanding their Alzheimer's disease portfolio with a new vectorized anti-Aβ antibody gene therapy research initiative and executing a license agreement with Sangamo for prion disease treatment.

Through their ongoing research and strategic collaborations, Voyager Therapeutics is pushing the boundaries of gene therapy to deliver groundbreaking solutions for patients